Bio & Pharma
EOFlow's insulin injection pump starts to be sold in UAE
The South Korean bio tech company is preparing to get approval in Saudi Arabia
By Feb 15, 2023 (Gmt+09:00)
1
Min read
Most Read
S.Korea's LS Materials set to boost earnings ahead of IPO process
NPS to commit $1.1 billion to external managers in 2024
Samsung Heavy Industries succeeds autonomous vessel navigation
Samsung shifts to emergency mode with 6-day work week for executives
Korean battery maker SK On expects business turnaround in H2
South Korea's medical device maker EOFlow Co. started selling the wearable insulin pump EOPatch in the United Arab Emirates.
The company said on Tuesday that it is generating sales in the Middle East after signing a deal with local distribution partner GulfDrug. It has been six months since it received item permission for EOPatch from the UAE Ministry of Health and Prevention in August last year.
EOPatch is an insulin pump that automatically injects insulin once a diabetic patient enters a blood sugar value into the device.
Following the UAE, the company is also preparing for item approval in Saudi Arabia. "The Middle East and North Africa market with great growth potential, with 54 million diabetic patients in total," said a company official.
Write to Jeong Min Nam at peux@hankyung.com
More to Read
-
Artificial intelligenceS.Korea's Lunit supplies breast cancer imaging solution to UAE
Feb 09, 2023 (Gmt+09:00)
1 Min read -
Business & PoliticsSouth Korean companies ink $6.1 billion MOUs with UAE partners
Jan 17, 2023 (Gmt+09:00)
3 Min read -
Korean foodKorea Ginseng Corp. intensifies marketing efforts in the UAE
Aug 09, 2022 (Gmt+09:00)
1 Min read
Comment 0
LOG IN